FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C.	20549
· ac · gcc· · ·,		_00.0

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							- ( , -				1 7							
Name and Address of Reporting Person*     Maeusli Heinz Christoph					2. Issuer Name <b>and</b> Ticker or Trading Symbol Lantheus Holdings, Inc. [ LNTH ]							(Ch	ieck all appli	ionship of Reporting all applicable) Director		Person(s) to Issuer  10% Owner		
	`	OLDINGS, INC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/19/2020								Officer below)	(give title		Other (specify below)		
(Street) NORTH BILLER (City)		4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person								
		Tab	le I - Non-	Deriva-	tive S	Securi	ities	Acc	quired,	Dis	posed o	f, or Be	neficial	ly Owned	l			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,		Code (Instr. 5)			ed (A) or tr. 3, 4 and	Benefici	es Formally (D) (Following (I) (II)		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) or (D)	Price		action(s)			(1130.4)		
Common stock 06/19/					9/2020		A		5,981	l A	\$0.0	0 5,	5,981		D			
		-	Γable II - D (€						,		,	or Ben ble secu	,	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	version Date Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)		Co	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ve es d d	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	ode V	(A)	,		Date Exercisab		Expiration Date	Title	Amount or Number of Shares					
Non- Qualified Stock Option (Right to Buy)	\$16.17	06/19/2020		I	A	17,	,481		06/19/202	0 1	12/13/2029	Common stock	17,481	(1)	17,48:	1	D	

## **Explanation of Responses:**

1. Received in exchange for a non-qualified stock option to acquire 56,393 shares of Progenics Pharmaceuticals, Inc. ("Progenics") for \$5.01 per share, in connection with the merger of Progenics pursuant to the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 20, 2020, by and among Lantheus Holdings, Inc. (the "Company"), Plato Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), and Progenics, pursuant to which Merger Sub merged with and into Progenics, with Progenics surviving as a wholly owned subsidiary of the Company (the "Merger").

## Remarks:

/s/ Daniel Niedzwiecki, 06/23/2020 attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.